Synthesis of Cucurbitacin B Derivatives as Potential Anti-Hepatocellular Carcinoma Agents. 2018

Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300353, China. geweizhi@aliyun.com.

Cucurbitacin B shows potent activity against tumor cells, but its high toxicity limits its application in the clinic. A series of cucurbitacin B derivatives was synthesized and evaluated for their anti-hepatocellular carcinoma (HCC) activities against the HepG-2 cell line. These compounds were also tested for their toxicity against the L-O2 normal cell line. The compound with the most potential, 10b, exhibited potent activity against the HepG-2 cell line with an IC50 value of 0.63 μM. Moreover, compound 10b showed the highest TI value (4.71), which is a 14.7-fold improvement compared to its parent compound cucurbitacin B. A preliminary molecular mechanism study of 10b indicated that 10b could inhibit P-STAT3 to induce the activation of mitochondrial apoptotic pathways. An in vivo acute toxicity study indicated that the compound 10b has preferable safety and tolerability compared with cucurbitacin B. These findings indicate that compound 10b might be considered as a lead compound for exploring effective anti-HCC drugs.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014315 Triterpenes A class of terpenes (the general formula C30H48) formed by the condensation of six isoprene units, equivalent to three terpene units. Triterpene,Triterpenoid,Triterpenoids
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D050796 STAT3 Transcription Factor A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-6 family members. STAT3 is constitutively activated in a variety of TUMORS and is a major downstream transducer for the CYTOKINE RECEPTOR GP130. APRF Transcription Factor,Acute-Phase Response Factor,IL6-Response Factor,LIF-Response Factor,STAT3 Protein,STAT3a Transcription Factor,STAT3b Transcription Factor,Signal Transducer and Activator of Transcription 3,Stat3alpha Transcription Factor,Stat3beta Transcription Factor,Acute Phase Response Factor,IL6 Response Factor,LIF Response Factor,Response Factor, Acute-Phase,Transcription Factor, APRF,Transcription Factor, STAT3,Transcription Factor, STAT3a,Transcription Factor, STAT3b,Transcription Factor, Stat3alpha,Transcription Factor, Stat3beta
D056945 Hep G2 Cells A human liver tumor cell line used to study a variety of liver-specific metabolic functions. Cell Line, Hep G2,Cell Line, Hepatoblastoma G2,Hep G2 Cell Line,HepG2 Cells,Hepatoblastoma G2 Cell Line,Cell, Hep G2,Cell, HepG2,Cells, Hep G2,Cells, HepG2,Hep G2 Cell,HepG2 Cell

Related Publications

Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
February 2017, European journal of medicinal chemistry,
Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
January 2022, Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents,
Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
January 2024, European journal of medicinal chemistry,
Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
February 2017, Molecules (Basel, Switzerland),
Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
June 2012, Bioorganic & medicinal chemistry letters,
Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
January 2012, Bioorganic & medicinal chemistry letters,
Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
March 1982, Il Farmaco; edizione scientifica,
Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
June 2011, Bioorganic & medicinal chemistry letters,
Weizhi Ge, and Xinyi Chen, and Fangzhi Han, and Zhongquan Liu, and Tianpeng Wang, and Mengmeng Wang, and Yue Chen, and Yahui Ding, and Quan Zhang
June 2007, European journal of medicinal chemistry,
Copied contents to your clipboard!